Drug repurposing (also known as drug repositioning, drug reprofiling, indication expansion or indication shift) involves establishing new medical uses for already known drugs, including approved, discontinued, shelved and experimental drugs. Although this strategy is far from new, it has gained considerable momentum in the last decade: about one-third of the approvals in recent years correspond to drug repurposing, and repurposed drugs currently generate around 25% of the annual revenue for the pharmaceutical industry [1]. Unsurprisingly, the strategy has thus been integrated in the life cycle management of pharmaceutical products. Public and non-for-profit organizations have released specific programs to promote drug repurposing initiatives (see, for instance, the successful Discovering New